title: Immunotherapy for Epstein-Barr virus-associated cancers in children.
abstract: Latent Epstein-Barr virus (EBV) infection is associated with several malignancies, including Burkitt's lymphoma, Hodgkin's disease, nasopharyngeal carcinoma, and post-transplant lymphoproliferative disease (LPD). The presence of EBV antigens in these tumors provides a target for immunotherapy approaches, and immunotherapy with EBV-specific cytotoxic T cells (CTLs) has proved effective in post-transplant LPDs, which are highly immunogenic tumors expressing type III latency. The malignant cells in Hodgkin's disease and nasopharyngeal carcinoma express type II latency and hence a more restricted pattern of EBV antigens. Trials with autologous EBV-specific CTL responses are under way in both of these diseases, and while some activity has been seen, no patient has yet been cured. This reduced CTL efficacy may reflect either downregulation of immunodominant EBV proteins, which are major CTL targets, or the ability of these tumors to evade the immune response by secreting inhibitory cytokines. Further improvement of EBV-specific CTL therapy for these type II latency tumors will require improved methods to activate and expand CTLs specific for the subdominant EBV genes expressed and to genetically modify the expanded CTLs to render them resistant to inhibitory cytokines. If these strategies to improve the therapeutic potential of immunotherapy for EBV-associated tumors prove successful, this type of treatment may be adapted to other tumors expressing known (viral) antigens.
authors.affiliation: Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas 77030, USA.
authors.forename: Karin C M
authors.initials: KC
authors.lastname: Straathof
authors.forename: Catherine M
authors.initials: CM
authors.lastname: Bollard
authors.forename: Cliona M
authors.initials: CM
authors.lastname: Rooney
authors.forename: Helen E
authors.initials: HE
authors.lastname: Heslop
mesh_terms: D000956:Antigens, Viral / Q000276:immunology; D002051:Burkitt Lymphoma / Q000276:immunology* / Q000628:therapy / Q000821:virology*; D002648:Child; D020031:Epstein-Barr Virus Infections / Q000150:complications*; D004854:Herpesvirus 4, Human / Q000235:genetics / Q000276:immunology*; D006689:Hodgkin Disease / Q000276:immunology* / Q000628:therapy / Q000821:virology*; D006801:Humans; D007167:Immunotherapy; D008232:Lymphoproliferative Disorders / Q000209:etiology / Q000276:immunology / Q000821:virology; D009303:Nasopharyngeal Neoplasms / Q000276:immunology* / Q000628:therapy / Q000821:virology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
chemical_list: D000956:Antigens, Viral